Objectives: Pazopanib is a tyrosine kinase inhibitor predominantly acting on tumor endothelium, and ixabepilone is a semisynthetic analog of epothilone B that promotes microtubule stabilization inducing tumor and tumor endothelial cell apoptosis. The purpose of this study was to determine the optimal tolerated dose (OTD) of the combination of pazopanib and ixabepilone for the treatment of metastatic previously treated solid tumors. Methods: Dose escalation started at 32mg/m2 of ixabepilone and increased to 40mg/m2. Pazopanib was administered initially at 400 mg and escalated at 200mg increments up to 800 mg. Pharmacokinetic analysis assessed effect of ixabepilone on pazopanib metabolism. Correlative studies evaluated changes in angiogenic cytokines. Results: Thirty-one patients (20 male and 11 female; median age, 58y) with ECOG PS of 0 or 1 were enrolled. Three patients had doselimiting toxicities (fatigue and neutropenia) at dose level 2 (ixabepi-lone 40 mg/m2 and pazopanib 400 mg), and therefore the ixabepilone dose was decreased (32 mg/m2) before escalating pazopanib to levels 3 and 4. One patient had a dose-limiting toxicity (thrombocytopenia) at dose level 4 (ixabepilone 32mg/m2 and pazopanib 800 mg). Dose level 3 was determined to be the OTD (pazopanib 600 mg and ixabepilone 32 mg/m2). The most common toxicities were cytopenias. A significant decrease in the level of sE-selectin was associated with improvement in progression free survival. Conclusions: The OTD for combination of pazopanib and ixabepilone was established. There was no impact of ixabepilone on pazopanib pharmacokinetics. The relationship between sE-selectin and progression free survival warrants further investigation.
|Original language||English (US)|
|Number of pages||8|
|Journal||American Journal of Clinical Oncology: Cancer Clinical Trials|
|State||Published - Jan 1 2016|
- Advanced solid tumor